Reports Q4 revenue $170M, consensus $169.6M. “We ended FY24 strong, delivering core revenue growth in our Sample Management Solutions and Multiomics businesses, and upholding our commitment to meaningfully expand margins,” stated John Marotta, President and CEO. “We are proud of the progress that we made in FY24, particularly in our Transformation Program Ascend 2026, and intend to carry that momentum forward to drive further performance, as proven by our FY25 guidance, which anticipates core revenue growth in the range of 3% to 5%, with continued margin expansion and a renewed focus on free cash flow.”